Search research articles
Contact Us
Filters
Showing results (51-60 of 129) with videos related to
Page
of 13
Sort By:
Progress in Clinical and Biological Research
|
January 1, 1987
The intrainfusion rebound platelet activation during continuous prostaglandin I2 infusion occurs at the receptor level
H Sinzinger, G Steurer, P Fitscha, et al.
VASA. Zeitschrift Fur Gefasskrankheiten
|
January 1, 1988
20 mg aspirin daily--evidence for a clinical future of this extremely low-dose in arterial disease?
H Sinzinger, K Silberbauer, J Kaliman, et al.
VASA. Zeitschrift Fur Gefasskrankheiten
|
October 19, 2000
Prostaglandin E1-therapy reduces circulating adhesion molecules (ICAM-1, E-selectin, VCAM-1) in peripheral vascular disease
B Palumbo, A Oguogho, P Fitscha, et al.
Lancet (London, England)
|
November 24, 1984
Effect of epoprostenol on platelet deposition on synthetic artery grafts
H Sinzinger, J O'Grady, P Fitscha, et al.
Thrombosis Research
|
May 15, 1989
Isradipine: a potent calcium blocker with beneficial effects on platelet function and vascular prostacyclin production
K Weiss, P Fitscha, J O'Grady, et al.
Progress in Clinical and Biological Research
|
January 1, 1987
Beneficial effect of prostaglandin E1 on smooth muscle cell proliferation
H Sinzinger, P Fitscha, T Zidek, et al.
European Journal of Clinical Pharmacology
|
January 1, 1990
Effects of taprostene, a stable prostacyclin analogue, on haemodynamics, platelet function and arachidonate metabolism in healthy volunteers
I Virgolini, P Fitscha, H Sinzinger, et al.
Acta Medica Austriaca
|
January 1, 1982
[Value of the detection of arteriosclerotic lesions with labeled autologous thrombocytes]
H Sinzinger, K Silberbauer, P Fitscha, et al.
Thrombosis Research
|
September 1, 1989
Effects of Hydergine on platelet deposition on "active" human carotid artery lesions and platelet function
G Steurer, P Fitscha, K Ettl, et al.
The New England Journal of Medicine
|
October 18, 1984
Extremely-low-dose aspirin (1 mg per day) renders human platelets more sensitive to antiaggregation prostaglandins
H Sinzinger, J O'Grady, P Fitscha, et al.
Page
of 13
Search research articles
Search
Showing results (51-60 of 129) with videos related to
Sort By:
Page
of 13
Progress in Clinical and Biological Research
|
January 1, 1987
The intrainfusion rebound platelet activation during continuous prostaglandin I2 infusion occurs at the receptor level
H Sinzinger, G Steurer, P Fitscha, et al.
VASA. Zeitschrift Fur Gefasskrankheiten
|
January 1, 1988
20 mg aspirin daily--evidence for a clinical future of this extremely low-dose in arterial disease?
H Sinzinger, K Silberbauer, J Kaliman, et al.
VASA. Zeitschrift Fur Gefasskrankheiten
|
October 19, 2000
Prostaglandin E1-therapy reduces circulating adhesion molecules (ICAM-1, E-selectin, VCAM-1) in peripheral vascular disease
B Palumbo, A Oguogho, P Fitscha, et al.
Lancet (London, England)
|
November 24, 1984
Effect of epoprostenol on platelet deposition on synthetic artery grafts
H Sinzinger, J O'Grady, P Fitscha, et al.
Thrombosis Research
|
May 15, 1989
Isradipine: a potent calcium blocker with beneficial effects on platelet function and vascular prostacyclin production
K Weiss, P Fitscha, J O'Grady, et al.
Progress in Clinical and Biological Research
|
January 1, 1987
Beneficial effect of prostaglandin E1 on smooth muscle cell proliferation
H Sinzinger, P Fitscha, T Zidek, et al.
European Journal of Clinical Pharmacology
|
January 1, 1990
Effects of taprostene, a stable prostacyclin analogue, on haemodynamics, platelet function and arachidonate metabolism in healthy volunteers
I Virgolini, P Fitscha, H Sinzinger, et al.
Acta Medica Austriaca
|
January 1, 1982
[Value of the detection of arteriosclerotic lesions with labeled autologous thrombocytes]
H Sinzinger, K Silberbauer, P Fitscha, et al.
Thrombosis Research
|
September 1, 1989
Effects of Hydergine on platelet deposition on "active" human carotid artery lesions and platelet function
G Steurer, P Fitscha, K Ettl, et al.
The New England Journal of Medicine
|
October 18, 1984
Extremely-low-dose aspirin (1 mg per day) renders human platelets more sensitive to antiaggregation prostaglandins
H Sinzinger, J O'Grady, P Fitscha, et al.
Page
of 13